Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Voyager Therapeutics closes $45mm Series A financing

Executive Summary

Third Rock Ventures launched Voyager Therapeutics Inc. and provided the start-up with $45mm in Series A financing to support work, over at least the next three years, on gene therapeutics for fatal CNS diseases. Third Rock, which has incubated Voyager for the last couple years, says it would be willing to add another VC, including a corporate backer, to later tranches.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies